ClinicalTrials.gg
Not yet recruitingNCT07516821Updated Apr 13, 2026

Efficacy of Topical Metformin in Psoriasis Vulgaris

An interventional study of Topical metformin 30% cream and Placebo in Psoriasis Vulgaris, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Psoriasis by Cairo University — 6 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · Cairo University.

Planned enrollment
5th of 20
55 · median 40
Started
2026
with 4 others
No phase
13 of 22
4 open now
Registered
19th of 22
by date

Among the 22 studies in Psoriasis by Cairo University, this one is the 5th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 13 with no phase, and was the 19th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 22 studies in Psoriasis by Cairo University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Psoriasis by Cairo University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if topical metformin works to treat mild psoriasis vulgaris. It will also learn about the safety of topical metformin. The main questions it aims to answer are:

Does topical metformin improve psoriatic plaques in early psoriasis? What medical problems do participants have when use topical metformin? Researchers will compare topical metformin to a placebo (a look-alike substance that contains no drug) to see if topical metformin works to treat psoriasis vulgaris.

Participants will:

put topical metformin or placebo twice daily for 2 months. Visit the clinic once every months for follow up. Keep a diary of their symptoms and any side effects.

Skin biopsy will be taken from psoriatic plaque before starting treatment and another one will be taken after 2 months of starting treatment to assess the level of IL-17.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years old
  • Patients of both genders
  • Patients with mild chronic plaque psoriasis ((PASI) \< 10, and body surface area (BSA) \< 10% and/or Dermatology Life Quality Index (DLQI) \<10).

Exclusion criteria

Exclusion Criteria:

  • Intake of anti-psoriatic systemic therapy within the last 3 months apart from retinoids, or topical treatments within the last 2 weeks.
  • Intake of systemic metformin.
  • Intake of other systemic drugs that exacerbate psoriasis as anti-malarial drugs, Angiotensin- converting-enzyme inhibitors (ACEI), Ca channel blockers (CCBs) and beta blockers or intake of non-steroidal anti- inflammatory drugs (NSAID) within the last 2 weeks.
  • Patients with psoriatic arthritis.
  • Patients with pustular psoriasis.
  • Pregnant and Lactating females.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (estimated)

Study arms

  • Active comparator
    Metformin

    patient with mild psoriasis with PASI less than 10% will receive topical metformin 30% cream twice daily

    Drug: Topical metformin 30% cream

  • Placebo comparator
    Placebo

    patients with mild psoriasis vulgaris will receive placebo cream twice daily

    Drug: Placebo

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metformin 30% loaded cream will be prepared using stearic acid as a lipid phase for group 1.

  • DrugPlacebo

    a plain similar cream (without metformin) will be prepared as a placebo.

06

What researchers measure

Primary outcomes

  1. Assessment and comparison of tissue levels of interleukin 17 (IL - 17) between the topical metformin and placebo group.

    Time frame: 8 weeks after starting treatment

  2. Comparison of percent PASI improvement from baseline between the topical metformin and placebo groups.

    Time frame: 8 weeks after starting treatment

Secondary outcomes

  1. Comparison of percentage of patients who achieved ≥4-point improvement from baseline worst itch numeric rating score (WI- NRS) between the topical metformin and placebo groups.

    Time frame: 8 weeks after starting treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jul 2026, 3 months later.

Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 3 months is below that.

Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 8, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Jul 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07516821
Lead sponsor
Cairo University
Responsible party
Yasmine Ahmed Mahmoud Obaid (Resident, Cairo University) — Principal investigator
First posted
Apr 8, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Yasmine A Obaid, MSc
Contact
yasmeenahmed013@gmail.com
02-01270047877

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion